Project ECHO Diabetes in the Time of COVID-19: DPP-4 Inhibitor, GLP-1 Receptor Agonist, & SGLT Inhibitor Therapies (Recorded Webinar)

Sunday, June 30, 2024, 12:00 AM - Tuesday, June 29, 2027, 11:59 PM, On Demand

This activity will address the urgent needs of patients with type 1 and type 2 diabetes who require complex diabetes treatment in the primary care setting in the time of COVID-19 by empowering and increasing the capacity of primary care providers (PCPs) and clinics to safely and effectively manage underserved patients who do not have access to routine specialty care. Led by a nationally/internationally renowned faculty team of diabetes experts (many of whom contribute to/co-author national guideline recommendations), this curriculum will spotlight various aspects of diabetes management for patients at high-risk for poor outcomes during the time of COVID-19.

  Original Release Date: July 21, 2020
  Review Date: April 3, 2024
  Expiration Date: June 29, 2027
  Estimated Time to Complete: 47 mins
  Registration Fee: FREE

View all Project ECHO Diabetes COVID-19 series information and resources HERE

AMA PRA Category 1 Credits™ (0.75 hours), Non-Physician Participation Credit (0.75 hours)

1. Discuss different non-insulin therapies for diabetes.
2. Identify patients who may benefit from these therapies.
3. Discuss potential risks vs. benefits of these therapies in the time of COVID-19.
4. Describe contraindications for these therapies in the time of COVID-19.

In support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation
American Medical Association (AMA)
Stanford Medicine designates this Enduring Material for a maximum of 0.75 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accessibility Statement
 Stanford University School of Medicine is committed to ensuring that its programs, services, goods and facilities are accessible to individuals with disabilities as specified under Section 504 of the Rehabilitation Act of 1973 and the Americans with Disabilities Amendments Act of 2008. 

Cultural and Linguistic Competency
The planners and speakers of this CME activity have been encouraged to address cultural issues relevant to their topic area for the purpose of complying with California Assembly Bill 1195. Moreover, the Stanford University School of Medicine Multicultural Health Portal contains many useful cultural and linguistic competency tools including culture guides, language access information and pertinent state and federal laws.  You are encouraged to visit the Multicultural Health Portal: http://lane.stanford.edu/portals/cultural.html

Bibliography/Reference list:  Sources cited in the activity. Additional resources located at diabetescovid.stanford.edu.

For ECHO Project questions, please contact:
  Division of Pediatric Endocrinology and Diabetes
  Email: [email protected]

For CME general questions, please contact 
     Email: [email protected]

Stanford Medicine adheres to the Standards for Integrity and Independence in Accredited Continuing Education.
There are no relevant financial relationships with ACCME-defined ineligible companies for anyone who was in control of the content of this activity.

This CME Series is supported in part by educational grants from Novo Nordisk and Pfizer, Inc.